Keytruda approved in Canada for advanced head and neck cancer
Keytruda is indicated for adult patients with resectable locally advanced head and neck squamous cell carcinoma, expressing PD-L1.
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery